PL358221A1 - Zastosowanie antagonisty ośrodkowych receptorów kanabinoidowych do wytwarzania leków użytecznych doułatwiania zaprzestania używania tytoniu - Google Patents

Zastosowanie antagonisty ośrodkowych receptorów kanabinoidowych do wytwarzania leków użytecznych doułatwiania zaprzestania używania tytoniu

Info

Publication number
PL358221A1
PL358221A1 PL01358221A PL35822101A PL358221A1 PL 358221 A1 PL358221 A1 PL 358221A1 PL 01358221 A PL01358221 A PL 01358221A PL 35822101 A PL35822101 A PL 35822101A PL 358221 A1 PL358221 A1 PL 358221A1
Authority
PL
Poland
Prior art keywords
receptor antagonist
smoking cessation
cannabinoid receptor
preparing medicines
central cannabinoid
Prior art date
Application number
PL01358221A
Other languages
English (en)
Other versions
PL201685B1 (pl
Inventor
Jean Charles Blanchard
Francois Menard
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of PL358221A1 publication Critical patent/PL358221A1/pl
Publication of PL201685B1 publication Critical patent/PL201685B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL358221A 2000-02-09 2001-02-07 Zastosowanie N-piperydyno-5-(4-chlorofenylo)-1-(2,4-dichlorofenylo)-4-metylopirazolo-3-karboksyamidu do wytwarzania leków PL201685B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
PCT/FR2001/000356 WO2001058450A2 (fr) 2000-02-09 2001-02-07 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Publications (2)

Publication Number Publication Date
PL358221A1 true PL358221A1 (pl) 2004-08-09
PL201685B1 PL201685B1 (pl) 2009-04-30

Family

ID=8846875

Family Applications (1)

Application Number Title Priority Date Filing Date
PL358221A PL201685B1 (pl) 2000-02-09 2001-02-07 Zastosowanie N-piperydyno-5-(4-chlorofenylo)-1-(2,4-dichlorofenylo)-4-metylopirazolo-3-karboksyamidu do wytwarzania leków

Country Status (32)

Country Link
US (2) US6930122B2 (pl)
EP (1) EP1257275B1 (pl)
JP (2) JP2003522145A (pl)
CN (1) CN1250220C (pl)
AR (1) AR028505A1 (pl)
AT (1) ATE292467T1 (pl)
AU (1) AU781827B2 (pl)
BG (2) BG110386A (pl)
BR (1) BR0108126A (pl)
CA (1) CA2397262C (pl)
CZ (1) CZ296685B6 (pl)
DE (1) DE60109903T2 (pl)
DK (1) DK1257275T3 (pl)
EE (1) EE04836B1 (pl)
ES (1) ES2240416T3 (pl)
FR (1) FR2804604B1 (pl)
HU (1) HU225328B1 (pl)
IL (1) IL150710A0 (pl)
IS (1) IS6450A (pl)
MX (1) MXPA02007766A (pl)
NO (1) NO324521B1 (pl)
NZ (1) NZ519924A (pl)
PL (1) PL201685B1 (pl)
PT (1) PT1257275E (pl)
RS (1) RS50404B (pl)
RU (1) RU2257207C2 (pl)
SI (1) SI1257275T1 (pl)
SK (1) SK284952B6 (pl)
TW (1) TWI243677B (pl)
UA (1) UA72783C2 (pl)
WO (1) WO2001058450A2 (pl)
ZA (1) ZA200205317B (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
JP2005500690A (ja) 2001-08-13 2005-01-06 ハネウェル・インターナショナル・インコーポレーテッド オーバーレイヤーパターンを使用してウェハに担持された半導体デバイスの電流制御を提供すること
CA2478338A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US7423067B2 (en) 2002-03-26 2008-09-09 Merck & Co., Inc. Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
JP4459629B2 (ja) 2002-04-12 2010-04-28 メルク エンド カムパニー インコーポレーテッド 二環式アミド
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
US7091216B2 (en) 2002-08-02 2006-08-15 Merck & Co., Inc. Substituted furo[2,3-b]pyridine derivatives
EP1546115A4 (en) 2002-09-27 2010-08-04 Merck Sharp & Dohme Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1575901B1 (en) 2002-12-19 2012-10-10 Merck Sharp & Dohme Corp. Substituted amides
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
EP1633733B1 (en) * 2003-05-20 2011-01-26 The University of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2005044785A1 (en) * 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
WO2006025069A2 (en) 2004-07-12 2006-03-09 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
BRPI0706623A2 (pt) * 2006-01-18 2011-04-12 Schering Corp moduladores de receptor canabinóide
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
WO2007121687A1 (en) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
AU2007312233B2 (en) * 2006-10-20 2012-09-20 Abbvie B.V. Micellar nanoparticles of chemical substances
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
EP2548874A3 (en) * 2007-06-28 2013-05-15 Intervet International B.V. Substituted piperazines as CB1 antagonists
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
JPWO2010018856A1 (ja) * 2008-08-13 2012-01-26 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Also Published As

Publication number Publication date
CN1250220C (zh) 2006-04-12
BG110386A (en) 2009-09-30
HUP0300237A2 (hu) 2003-07-28
DE60109903T2 (de) 2006-02-09
ES2240416T3 (es) 2005-10-16
EP1257275B1 (fr) 2005-04-06
NZ519924A (en) 2005-01-28
HK1051140A1 (en) 2003-07-25
SI1257275T1 (en) 2005-10-31
NO20023765L (no) 2002-10-09
US20050187253A1 (en) 2005-08-25
TWI243677B (en) 2005-11-21
RU2002118309A (ru) 2004-02-20
BR0108126A (pt) 2003-01-28
PT1257275E (pt) 2005-07-29
FR2804604B1 (fr) 2005-05-27
RS50404B (sr) 2009-12-31
DE60109903D1 (de) 2005-05-12
CA2397262C (en) 2007-09-11
UA72783C2 (en) 2005-04-15
HU225328B1 (en) 2006-09-28
AU3562001A (en) 2001-08-20
CZ296685B6 (cs) 2006-05-17
BG65856B1 (bg) 2010-03-31
IL150710A0 (en) 2003-02-12
YU59002A (sh) 2005-07-19
IS6450A (is) 2002-06-28
EE200200439A (et) 2003-12-15
DK1257275T3 (da) 2005-08-08
EE04836B1 (et) 2007-06-15
JP2010018622A (ja) 2010-01-28
WO2001058450A2 (fr) 2001-08-16
JP2003522145A (ja) 2003-07-22
SK11292002A3 (sk) 2003-02-04
US6930122B2 (en) 2005-08-16
US20030087933A1 (en) 2003-05-08
CN1406128A (zh) 2003-03-26
ATE292467T1 (de) 2005-04-15
ZA200205317B (en) 2003-09-04
NO20023765D0 (no) 2002-08-08
EP1257275A2 (fr) 2002-11-20
MXPA02007766A (es) 2002-10-11
CA2397262A1 (en) 2001-08-16
FR2804604A1 (fr) 2001-08-10
AR028505A1 (es) 2003-05-14
HUP0300237A3 (en) 2003-09-29
RU2257207C2 (ru) 2005-07-27
BG106946A (bg) 2003-05-30
AU781827B2 (en) 2005-06-16
NO324521B1 (no) 2007-11-12
CZ20022698A3 (cs) 2002-11-13
SK284952B6 (sk) 2006-03-02
WO2001058450A3 (fr) 2002-04-25
PL201685B1 (pl) 2009-04-30

Similar Documents

Publication Publication Date Title
NO20023765D0 (no) Anvendelse av sentrale cannabinoid-reseptorantagonister for fremstilling av medisiner utformet for å gjöre rökestans lettere
UA66900C2 (uk) Похідні піразолкарбонової кислоти, спосіб їх виготовлення, фармацевтична композиція, що їх містить
UA49056C2 (uk) Фармацевтична композиція для перорального застосування аміду n-піперидин-5-(4-хлорфеніл)-1-(2,4-дихлорфеніл)-4-метилпіразол-3-карбонової кислоти, його солей і сольватів та спосіб її отримання
CA2136893A1 (en) Substituted n-piperidino-pyrazole-3-carboxamide
MXPA03001421A (es) Pirazoles sustituidos.
HUP0300867A3 (en) Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof and pharmaceutical compositions containing the compounds
JP2003522145A5 (pl)
HUP0303108A3 (en) Substituted pyrazoles and pharmaceutical compositions containing them
MXPA03001593A (es) Derivados de pirazola fusionada siendo inhibidores de quinasa de proteina.
IL167038A (en) Pyrazole derivatives, pharmaceutical compositions containing the same, use thereof in the manufacture of medicaments and intermediate for production thereof
EP1224173A4 (en) PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS
ATE480539T1 (de) Bizyklische pyrazole wirksam als kinase inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
IL155236A0 (en) Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
IS7126A (is) Lyfjablanda á formi sviflausnar, sem gerð hefur verið stöðug, og gefin er inn um munn
YU7804A (sh) Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
FR2849032B1 (fr) Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique
CY1112078T1 (el) Χρηση των ανταγωνιστων του cb1 υποδοχεα για την παρασκευη ενος σκευασματος που θα χρησιμοποιηθει για τη θεραπεια των ηπατικων νοσων
WO2001049651A3 (de) Aminomethyl-phenyl-cyclohexanonderivate
MXPA04000953A (es) Derivados sustituidos del acido 5,6,6a,11b-tetrahidro-7-oxa-aza-benzo[c]fluoren-6-carboxilico como antagonista de nmda.
TH62253A (th) การใช้เซ็นทรัลแคนนาบินอยด์รีเซพเตอร์แอนแทกโกนิสต์ เพื่อการเตรียมผลิตภัณฑ์ยาซึ่งใช้ประโยชน์เพื่อการช่วยให้เลิกสูบบุหรี่
ITGE20000017V0 (it) Boccaglio per erogatori di apparecchi respiratori subacquei.
MD2551G2 (ro) Utilizarea soluţiilor ozonate acceptabile farmaceutic ozonate pentru tratamentul micozelor cavităţii bucale
GB0020576D0 (en) Fused pyrazole derivatives

Legal Events

Date Code Title Description
VDSO Invalidation of derivated patent or utility model

Ref document number: 385191

Country of ref document: PL

LAPS Decisions on the lapse of the protection rights

Effective date: 20100207